$2,749.31 general Payment -- Regeneron Pharmaceuticals to Dr. Gregory Evans
Regeneron Pharmaceuticals Pays Dermatologist Gregory Evans for Services Related to Rybelsus
This page provides a detailed analysis of a $2,749.31 general payment from Regeneron Pharmaceuticals to Dr. Gregory Evans. Data is from the CMS Open Payments (Sunshine Act) database.
Payment Details
| Field | Value |
|---|---|
| Amount | $2,749.31 |
| Payment Type | general |
| Payment Nature | Compensation for services other than consulting |
| Pharmaceutical Company | Regeneron Pharmaceuticals |
| Physician | Dr. Gregory Evans |
| NPI Number | 1232540169 |
| Physician Specialty | Dermatology |
| Location | Detroit, MI |
| Date of Payment | 2026-03-05 |
| Related Drug/Device | Rybelsus |
| Conflict Assessment | Low -- Routine |
AI-Powered Analysis of This Payment
The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.
Regeneron Pharmaceuticals made a $2.7K general payment to Gregory Evans, a Dermatology specialist in Detroit, MI. The payment was associated with Rybelsus. The payment of $2,749.31 to Dr. Gregory Evans from Regeneron Pharmaceuticals is for services other than consulting. The payment is associated with the drug Rybelsus, a treatment for type 2 diabetes. This payment occurred on March 5, 2026, in Detroit, MI.
Patient Guidance: What This Payment Means for You
This payment is for services rendered by your doctor related to the medication Rybelsus. It does not represent a direct payment to you as a patient. Always discuss your treatment options with your healthcare provider and ask about alternatives.
Payment Context: Is This Amount Normal?
Payments for services other than consulting in dermatology can vary widely depending on the nature of the service and the physician's engagement with the pharmaceutical company.
Regulatory Context: Sunshine Act Requirements
This payment falls under the Sunshine Act provisions of the Affordable Care Act, requiring disclosure of financial relationships between drug and device manufacturers and physicians.
Related Topics
This payment is related to the following healthcare transparency topics:
- pharmaceutical-payments
- physician-compensation
- regeneron-pharmaceuticals
- rybelsus
- dermatology
- cms-open-payments
Understanding general Payments
general payments are one of several categories of financial transfers from pharmaceutical and medical device companies to physicians that must be reported under the Sunshine Act. Understanding the type and context of a payment is important for evaluating its significance. Not all payments are equal -- a research grant has very different implications than a promotional speaking fee.
Frequently Asked Questions About This Payment
What was this $2.7K payment for?
This was a general payment of $2.7K from Regeneron Pharmaceuticals to Gregory Evans, categorized as "Compensation for services other than consulting". It was associated with Rybelsus. The payment was reported under the Sunshine Act (CMS Open Payments).
Does Gregory Evans accept pharmaceutical money?
Yes, Gregory Evans received this $2.7K payment from Regeneron Pharmaceuticals. Under the Sunshine Act, pharmaceutical companies must report all payments to physicians exceeding $10. You can view Gregory Evans's full payment history on the CMS Open Payments database or on this site.
Is it legal for doctors to accept pharma payments?
Yes, it is legal for physicians to receive payments from pharmaceutical companies. The Physician Payments Sunshine Act (2010) requires transparency by mandating that companies report all payments exceeding $10 to CMS. These payments include consulting fees, meals, travel, speaking fees, and research grants. The law does not prohibit payments but ensures public disclosure.
Should I be concerned about this general payment?
A general payment of $2.7K should be evaluated in context. Payment does not imply wrongdoing, but patients have the right to ask their doctor about pharmaceutical relationships.
How do I talk to my doctor about pharma relationships?
You can ask your doctor directly: "Do you receive payments from pharmaceutical companies?" and "Does this affect which medications you prescribe?" Most doctors will answer honestly. You can also verify payment data yourself through CMS Open Payments (openpaymentsdata.cms.gov). Consider asking about generic alternatives and whether the prescribed medication is the best option regardless of manufacturer relationships.
What types of pharma payments are most concerning?
Ownership interests and large consulting/speaking fees are generally considered more significant than meals or small educational grants. Research payments typically fund clinical studies and are common in academic medicine. The total volume and concentration of payments from a single company may be more telling than any individual payment. Patterns matter more than individual transactions.
Does pharma money affect what my doctor prescribes?
Research shows that even small payments can influence prescribing behavior. Studies published in JAMA Internal Medicine found that physicians who received meals costing as little as $20 were more likely to prescribe the promoted brand-name drug. However, many physician-industry interactions are legitimate professional activities. The key is transparency and awareness.
How does this compare to other doctors in Dermatology?
To compare this payment against Dermatology averages, check the full specialty breakdown on CMS Open Payments. Payment amounts vary widely by specialty and type. Dermatology physicians may receive payments for consulting, speaking, or research that are standard for the field. Individual payments should be evaluated in the context of the doctor's full payment history.
What does this payment reveal about Gregory Evans's relationship with Regeneron Pharmaceuticals?
The payment is categorized as 'general' and for 'Compensation for services other than consulting'. This $2.7K general payment is part of the transparency data reported under the Sunshine Act.
Is this payment amount typical for Dermatology?
The specific drug mentioned is Rybelsus, indicating a potential focus on diabetes care within dermatology.
What should patients do after learning about this payment?
This payment is for services rendered by your doctor related to the medication Rybelsus. It does not represent a direct payment to you as a patient.
What else should I know about this general payment?
The payment date is in the future (2026), which is unusual for historical CMS Open Payments data.
Related Reports
Data from CMS Open Payments. Payment does not imply wrongdoing. Consult your healthcare provider about any concerns.